Glaukos CorpNYSE:GKOS
- LAST PRICE113.0150
- TODAY'S CHANGE (%)-1.3250 (-1.1588%)
- Bid / Lots112.9700/ 2
- Ask / Lots113.0700/ 2
- Open / Previous Close113.2000 / 114.3400
- Day Range
- 52 Week Range
- Volume90,211
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GKOS |
|---|---|---|
| 09:32 ET | 2492 | 113 |
| 09:34 ET | 100 | 112.79 |
| 09:36 ET | 125 | 113.05 |
| 09:41 ET | 1025 | 112.43 |
| 09:43 ET | 520 | 112.38 |
| 09:50 ET | 100 | 112.39 |
| 09:52 ET | 1699 | 113.55 |
| 09:54 ET | 200 | 113.5 |
| 09:56 ET | 350 | 113.46 |
| 09:57 ET | 600 | 113.415 |
| 10:01 ET | 300 | 113.44 |
| 10:03 ET | 1500 | 113.075 |
| 10:06 ET | 400 | 113.035 |
| 10:08 ET | 100 | 112.89 |
| 10:10 ET | 3390 | 112.985 |
| 10:12 ET | 100 | 112.98 |
| 10:14 ET | 900 | 112.99 |
| 10:15 ET | 1128 | 112.68 |
| 10:17 ET | 1412 | 112.71 |
| 10:19 ET | 1200 | 112.715 |
| 10:21 ET | 100 | 112.58 |
| 10:24 ET | 1856 | 112.99 |
| 10:26 ET | 709 | 113.425 |
| 10:28 ET | 300 | 113.19 |
| 10:30 ET | 400 | 112.85 |
| 10:32 ET | 600 | 113.04 |
| 10:33 ET | 929 | 112.955 |
| 10:35 ET | 4300 | 112.895 |
| 10:37 ET | 900 | 112.9 |
| 10:39 ET | 303 | 112.7 |
| 10:42 ET | 1780 | 112.89 |
| 10:44 ET | 700 | 112.8 |
| 10:46 ET | 700 | 112.62 |
| 10:48 ET | 301 | 112.26 |
| 10:50 ET | 1000 | 112.155 |
| 10:51 ET | 1730 | 112.54 |
| 10:53 ET | 300 | 112.56 |
| 10:55 ET | 963 | 112.47 |
| 10:57 ET | 200 | 112.11 |
| 11:00 ET | 700 | 111.93 |
| 11:02 ET | 3367 | 112.31 |
| 11:04 ET | 700 | 112.5 |
| 11:06 ET | 900 | 112.655 |
| 11:08 ET | 1006 | 112.85 |
| 11:09 ET | 300 | 112.88 |
| 11:15 ET | 200 | 112.93 |
| 11:18 ET | 200 | 113.005 |
| 11:20 ET | 1544 | 112.68 |
| 11:22 ET | 300 | 112.675 |
| 11:24 ET | 400 | 112.53 |
| 11:26 ET | 2270 | 113.13 |
| 11:27 ET | 100 | 112.85 |
| 11:29 ET | 1506 | 112.885 |
| 11:31 ET | 3100 | 112.965 |
| 11:33 ET | 950 | 112.99 |
| 11:36 ET | 900 | 112.92 |
| 11:38 ET | 500 | 113 |
| 11:40 ET | 686 | 112.975 |
| 11:42 ET | 2069 | 113.11 |
| 11:44 ET | 1551 | 113.04 |
| 11:49 ET | 315 | 113.01 |
| 11:51 ET | 1123 | 113.015 |
Yesterday
DJ Glaukos Is Maintained at Overweight by Wells Fargo, from 21 hours ago by Dow Jones
21 hours ago by Dow Jones
May 28, 2024
Glaukos Announces Participation in Upcoming Investor Conferences, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 22, 2024
DJ Glaukos Is Maintained at Buy by Citigroup, from 1:36PM ET on Wednesday May 22, 2024 by Dow Jones
1:36PM ET on Wednesday May 22, 2024 by Dow Jones
May 6, 2024
DJ Glaukos Raised to Buy From Hold by Jefferies, from 8:46AM ET on Monday May 06, 2024 by Dow Jones
8:46AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Glaukos Corp | 5.7B | -39.2x | --- |
Lantheus Holdings Inc | 5.7B | 12.5x | +35.30% |
Inspire Medical Systems Inc | 4.7B | -275.8x | --- |
Merit Medical Systems Inc | 4.7B | 47.1x | +14.05% |
Stevanato Group SpA | 6.1B | 35.0x | --- |
Axonics Inc | 3.4B | -213.6x | --- |
Company Information
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Contact Information
- Headquarters
- 1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
- Phone
- 949-367-9600
- Fax
- 949-367-9984
Executives
- Chairman of the Board, Chief Executive Officer
- Thomas Burns
- President, Chief Operating Officer
- Joseph Gilliam
- Chief Financial Officer, Senior Vice President
- Alex Thurman
- Chief Development Officer
- Tomas Navratil
- Lead Independent Director
- Mark Foley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7B |
|---|---|
Revenue (TTM) | $326.4M |
Shares Outstanding | 50.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.09 |
EPS | $-2.88 |
Book Value | $9.40 |
P/E Ratio | -39.2x |
Price/Sales (TTM) | 17.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -41.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
